Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease

Kranti A. Mapuskar, Hsiang Wen, Danniele G. Holanda, Prerna Rastogi, Emily Steinbach, Rachel Han, Mitchell C. Coleman, Massimo Attanasio, Dennis P. Riley, Douglas R. Spitz, Bryan G. Allen, Diana Zepeda-Orozco

Research output: Contribution to journalArticle

Abstract

Severe and recurrent cisplatin-induced acute kidney injury (AKI) as part of standard cancer therapy is a known risk factor for development of chronic kidney disease (CKD). The specific role of superoxide (O2 •-)-mediated disruption of mitochondrial oxidative metabolism in CKD after cisplatin treatment is unexplored. Cisplatin is typically administered in weekly or tri-weekly cycles as part of standard cancer therapy. To investigate the role of O2 •- in predisposing patients to future renal injury and in CKD, mice were treated with cisplatin and a mitochondrial-specific, superoxide dismutase (SOD) mimetic, GC4419. Renal function, biomarkers of oxidative stress, mitochondrial oxidative metabolism, and kidney injury markers, as well as renal histology, were assessed to evaluate the cellular changes that occur one week and one month (CKD phase) after the cisplatin insult. Cisplatin treatment resulted in persistent upregulation of kidney injury markers, increased steady-state levels of O2 •-, increased O2 •--mediated renal tubules damage, and upregulation of mitochondrial electron transport chain (ETC) complex I activity both one week and one month following cisplatin treatment. Treatment with a novel, clinically relevant, small-molecule superoxide dismutase (SOD) mimetic, GC4419, restored mitochondrial ETC complex I activity to control levels without affecting complexes II–IV activity, as well as ameliorated cisplatin-induced kidney injury. These data support the hypothesis that increased mitochondrial O2 •- following cisplatin administration, as a result of disruptions of mitochondrial metabolism, may be an important contributor to both AKI and CKD progression.

LanguageEnglish (US)
Pages98-106
Number of pages9
JournalRedox Biology
Volume20
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Chronic Renal Insufficiency
Superoxides
Cisplatin
Kidney
Metabolism
Electron Transport Complex I
Wounds and Injuries
Acute Kidney Injury
Superoxide Dismutase
Up-Regulation
Therapeutics
Histology
Oxidative stress
Level control
Biomarkers
Disease Progression
Neoplasms
Oxidative Stress
Molecules

Keywords

  • Cisplatin
  • Kidney injury
  • Mitochondrial metabolism
  • Superoxide
  • Superoxide dismutase mimetic

ASJC Scopus subject areas

  • Biochemistry
  • Organic Chemistry

Cite this

Mapuskar, K. A., Wen, H., Holanda, D. G., Rastogi, P., Steinbach, E., Han, R., ... Zepeda-Orozco, D. (2019). Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease. Redox Biology, 20, 98-106. https://doi.org/10.1016/j.redox.2018.09.020

Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease. / Mapuskar, Kranti A.; Wen, Hsiang; Holanda, Danniele G.; Rastogi, Prerna; Steinbach, Emily; Han, Rachel; Coleman, Mitchell C.; Attanasio, Massimo; Riley, Dennis P.; Spitz, Douglas R.; Allen, Bryan G.; Zepeda-Orozco, Diana.

In: Redox Biology, Vol. 20, 01.01.2019, p. 98-106.

Research output: Contribution to journalArticle

Mapuskar, KA, Wen, H, Holanda, DG, Rastogi, P, Steinbach, E, Han, R, Coleman, MC, Attanasio, M, Riley, DP, Spitz, DR, Allen, BG & Zepeda-Orozco, D 2019, 'Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease' Redox Biology, vol. 20, pp. 98-106. https://doi.org/10.1016/j.redox.2018.09.020
Mapuskar, Kranti A. ; Wen, Hsiang ; Holanda, Danniele G. ; Rastogi, Prerna ; Steinbach, Emily ; Han, Rachel ; Coleman, Mitchell C. ; Attanasio, Massimo ; Riley, Dennis P. ; Spitz, Douglas R. ; Allen, Bryan G. ; Zepeda-Orozco, Diana. / Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease. In: Redox Biology. 2019 ; Vol. 20. pp. 98-106.
@article{69b3a8c3da624769b2db485358068eab,
title = "Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease",
abstract = "Severe and recurrent cisplatin-induced acute kidney injury (AKI) as part of standard cancer therapy is a known risk factor for development of chronic kidney disease (CKD). The specific role of superoxide (O2 •-)-mediated disruption of mitochondrial oxidative metabolism in CKD after cisplatin treatment is unexplored. Cisplatin is typically administered in weekly or tri-weekly cycles as part of standard cancer therapy. To investigate the role of O2 •- in predisposing patients to future renal injury and in CKD, mice were treated with cisplatin and a mitochondrial-specific, superoxide dismutase (SOD) mimetic, GC4419. Renal function, biomarkers of oxidative stress, mitochondrial oxidative metabolism, and kidney injury markers, as well as renal histology, were assessed to evaluate the cellular changes that occur one week and one month (CKD phase) after the cisplatin insult. Cisplatin treatment resulted in persistent upregulation of kidney injury markers, increased steady-state levels of O2 •-, increased O2 •--mediated renal tubules damage, and upregulation of mitochondrial electron transport chain (ETC) complex I activity both one week and one month following cisplatin treatment. Treatment with a novel, clinically relevant, small-molecule superoxide dismutase (SOD) mimetic, GC4419, restored mitochondrial ETC complex I activity to control levels without affecting complexes II–IV activity, as well as ameliorated cisplatin-induced kidney injury. These data support the hypothesis that increased mitochondrial O2 •- following cisplatin administration, as a result of disruptions of mitochondrial metabolism, may be an important contributor to both AKI and CKD progression.",
keywords = "Cisplatin, Kidney injury, Mitochondrial metabolism, Superoxide, Superoxide dismutase mimetic",
author = "Mapuskar, {Kranti A.} and Hsiang Wen and Holanda, {Danniele G.} and Prerna Rastogi and Emily Steinbach and Rachel Han and Coleman, {Mitchell C.} and Massimo Attanasio and Riley, {Dennis P.} and Spitz, {Douglas R.} and Allen, {Bryan G.} and Diana Zepeda-Orozco",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.redox.2018.09.020",
language = "English (US)",
volume = "20",
pages = "98--106",
journal = "Redox Biology",
issn = "2213-2317",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease

AU - Mapuskar, Kranti A.

AU - Wen, Hsiang

AU - Holanda, Danniele G.

AU - Rastogi, Prerna

AU - Steinbach, Emily

AU - Han, Rachel

AU - Coleman, Mitchell C.

AU - Attanasio, Massimo

AU - Riley, Dennis P.

AU - Spitz, Douglas R.

AU - Allen, Bryan G.

AU - Zepeda-Orozco, Diana

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Severe and recurrent cisplatin-induced acute kidney injury (AKI) as part of standard cancer therapy is a known risk factor for development of chronic kidney disease (CKD). The specific role of superoxide (O2 •-)-mediated disruption of mitochondrial oxidative metabolism in CKD after cisplatin treatment is unexplored. Cisplatin is typically administered in weekly or tri-weekly cycles as part of standard cancer therapy. To investigate the role of O2 •- in predisposing patients to future renal injury and in CKD, mice were treated with cisplatin and a mitochondrial-specific, superoxide dismutase (SOD) mimetic, GC4419. Renal function, biomarkers of oxidative stress, mitochondrial oxidative metabolism, and kidney injury markers, as well as renal histology, were assessed to evaluate the cellular changes that occur one week and one month (CKD phase) after the cisplatin insult. Cisplatin treatment resulted in persistent upregulation of kidney injury markers, increased steady-state levels of O2 •-, increased O2 •--mediated renal tubules damage, and upregulation of mitochondrial electron transport chain (ETC) complex I activity both one week and one month following cisplatin treatment. Treatment with a novel, clinically relevant, small-molecule superoxide dismutase (SOD) mimetic, GC4419, restored mitochondrial ETC complex I activity to control levels without affecting complexes II–IV activity, as well as ameliorated cisplatin-induced kidney injury. These data support the hypothesis that increased mitochondrial O2 •- following cisplatin administration, as a result of disruptions of mitochondrial metabolism, may be an important contributor to both AKI and CKD progression.

AB - Severe and recurrent cisplatin-induced acute kidney injury (AKI) as part of standard cancer therapy is a known risk factor for development of chronic kidney disease (CKD). The specific role of superoxide (O2 •-)-mediated disruption of mitochondrial oxidative metabolism in CKD after cisplatin treatment is unexplored. Cisplatin is typically administered in weekly or tri-weekly cycles as part of standard cancer therapy. To investigate the role of O2 •- in predisposing patients to future renal injury and in CKD, mice were treated with cisplatin and a mitochondrial-specific, superoxide dismutase (SOD) mimetic, GC4419. Renal function, biomarkers of oxidative stress, mitochondrial oxidative metabolism, and kidney injury markers, as well as renal histology, were assessed to evaluate the cellular changes that occur one week and one month (CKD phase) after the cisplatin insult. Cisplatin treatment resulted in persistent upregulation of kidney injury markers, increased steady-state levels of O2 •-, increased O2 •--mediated renal tubules damage, and upregulation of mitochondrial electron transport chain (ETC) complex I activity both one week and one month following cisplatin treatment. Treatment with a novel, clinically relevant, small-molecule superoxide dismutase (SOD) mimetic, GC4419, restored mitochondrial ETC complex I activity to control levels without affecting complexes II–IV activity, as well as ameliorated cisplatin-induced kidney injury. These data support the hypothesis that increased mitochondrial O2 •- following cisplatin administration, as a result of disruptions of mitochondrial metabolism, may be an important contributor to both AKI and CKD progression.

KW - Cisplatin

KW - Kidney injury

KW - Mitochondrial metabolism

KW - Superoxide

KW - Superoxide dismutase mimetic

UR - http://www.scopus.com/inward/record.url?scp=85054213869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054213869&partnerID=8YFLogxK

U2 - 10.1016/j.redox.2018.09.020

DO - 10.1016/j.redox.2018.09.020

M3 - Article

VL - 20

SP - 98

EP - 106

JO - Redox Biology

T2 - Redox Biology

JF - Redox Biology

SN - 2213-2317

ER -